Drug Trial Radar · NCT04168190
A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)
Last checked: Nov 19, 2026Latest source record: Sep 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
600
Actual
Start
Dec 6, 2019
Primary completion
Jul 12, 2021
Study completion Jul 12, 2021
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1 and Phase 2 study will evaluate the safety, tolerability and immunogenicity of V116 when administered to adults. Phase 1 has no formal hypothesis. The primary hypotheses for Phase 2 are: V116 is noninferior to Pneumovax™23 as measured by the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) for the common serotypes at 30 days postvaccination and that the serotype-specific OPA GMTs for the unique serotypes in V116 at 30 days postvaccination are statistically significantly greater following vaccination with V116 than those following vaccination with Pneumovax™23.
Conditions
- Pneumonia, Pneumococcal
Interventions
V116Biological
Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
Pneumovax™23Biological
Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Percentage of Participants With a Solicited Injection-site Adverse Event (AE)Time frame: Up to 5 days post-vaccination
- Phase 1: Percentage of Participants With a Solicited Systemic AETime frame: Up to 5 days post-vaccination
- Phase 1: Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)Time frame: Up to Day 195
- Phase 2: Percentage of Participants With a Solicited Injection-site AETime frame: Up to 5 days post-vaccination
- Phase 2: Percentage of Participants With a Solicited Systemic AETime frame: Up to 5 days post-vaccination
- Phase 2: Percentage of Participants With Vaccine-related SAEsTime frame: Up to Day 293
- Phase 2: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in V116 and Pneumovax™23Time frame: 30 days post vaccination
- Phase 2: Serotype-specific OPA GMTs for the Unique Serotypes in V116Time frame: 30 days post vaccination
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Simon Williamson Clinic ( Site 0004)
Birmingham, Alabama
Central Arizona Medical Associates ( Site 0003)
Mesa, Arizona
Clinical Research of South Florida ( Site 0008)
Coral Gables, Florida
Indago Research & Health Center, Inc ( Site 0011)
Hialeah, Florida
Research Centers of America, LLC ( Site 0001)
Hollywood, Florida
QPS Miami Research Associates ( Site 0016)
Miami, Florida
L&C Professional Medical Research Institute ( Site 0009)
Miami, Florida
Advanced Medical Research Institute ( Site 0010)
Miami, Florida
Optimal Research ( Site 0006)
Peoria, Illinois
Benchmark Research ( Site 0012)
Metairie, Louisiana
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0018)
Troy, Michigan
Meridian Clinical Research, LLC ( Site 0024)
Norfolk, Nebraska
Wake Research Clinical Research Center of Nevada, LLC ( Site 0014)
Las Vegas, Nevada
Meridian Clinical Research, LLC ( Site 0025)
Endwell, New York
Rochester Clinical Research, Inc. ( Site 0002)
Rochester, New York
PriMED Clinical Research ( Site 0021)
Dayton, Ohio
Advanced Medical Research ( Site 0017)
Maumee, Ohio
Kaiser Permanente Center for Health Research ( Site 0015)
Portland, Oregon
Diagnostics Research Group ( Site 0013)
San Antonio, Texas
Advanced Clinical Research ( Site 0022)
West Jordan, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.